Pharmacogenetics: Opportunities and Challenges for Health Innovation

Pharmacogenetics helps us understand the relationship between an individual’s genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.
- Click to access:
-
Click to download PDF - 1.21MBPDF
-
Click to Read online and shareREAD
Regulatory Authorities and Reimbursement Mechanisms
This chapter looks at the role of regulators and reimbursement systems in facilitating the uptake of pharmacogenetics by health-care systems. Regulators and coverage policies will be strong factors in the rate of diffusion of pharmacogenetics. Reimbursement policies and cost-containment strategies for drug and test-use policies and clinical guidelines will be very important. The challenges for payers and the trade-offs they may have to make are also considered.
- Click to access:
-
Click to download PDF - 470.20KBPDF
-
Click to Read online and shareREAD